Christopher James Frankenfield - 03 Aug 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Operating Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
03 Aug 2024
Net transactions value
$0
Form type
4
Filing time
06 Aug 2024, 20:00:06 UTC
Previous filing
03 May 2024
Next filing
03 Jan 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +52,000 $0.000000 52,000 03 Aug 2024 Common Stock 52,000 $0.8950 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on August 3, 2024 and will vest in equal monthly installments beginning on September 1, 2024 through August 1, 2028.